Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2101053 | 0.89 | PIN1 (0.43) | MPO | |
| SCHEMBL2098277 | 0.82 | NPC1 (0.31) | NPC1KDM4EMAPK1MAPTRAB9A | |
| SCHEMBL2097020 | 0.80 | NPC1 (0.31) | NPC1KDM4EMAPK1MAPTRAB9A | |
| SCHEMBL2098275 | 0.77 | HDAC1 (0.36) | POLBKMT2A | |
| SCHEMBL2098271 | 0.77 | HDAC1 (0.36) | POLBKMT2A | |
| SCHEMBL2097018 | 0.73 | MGMT (0.37) | NPC1KDM4EMAPK1MAPTRAB9A | |
| SCHEMBL2101050 | 0.71 | PIN1 (0.43) | MPO | |
| SCHEMBL2098056 | 0.71 | PIN1 (0.41) | — | |
| SCHEMBL2097013 | 0.70 | HDAC1 (0.41) | — | |
| SCHEMBL2097015 | 0.70 | HDAC1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730298-B1 | SPECIFIC SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | EPFL ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-8163479-B2 | Specific substrates for O6-alkylguanine-DNA alkyltransferase | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20070243568-A1 | Specific Substrates for O6-Alkylguanine-Dna Alkyltransferase | EPFL ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243568-A1 | Specific Substrates for O6-Alkylguanine-Dna Alkyltransferase | AGT, AGXT, AGTR1 | NPC1 3880/4885KDM4E 3573/4885MAPK1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.